Antigenics history

	2007
June	GlaxoSmithKline (GSK) launched a Phase 3 clinical trial evaluating its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in non-small cell lung cancer. The vaccine contains GSK’s proprietary adjuvant system, which includes Antigenics’ QS-21 Stimulon adjuvant, for which Antigenics will receive future milestone payments and product royalties upon successful development and commercialization.
May	Antigenics presented end-of-study results from its Phase 3 trial of Oncophage in kidney cancer at the annual meeting of the American Urological Association. The study showed that Oncophage significantly prolonged recurrence-free survival and improved overall survival in a large subgroup of intermediate-risk patients.
April	An oral presentation of updated data from a Phase 1/2 investigator-sponsored trial of Oncophage in recurrent, high-grade glioma was presented at the 75th annual meeting of the American Association of Neurological Surgeons. Preliminary results from the study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco, showed that Oncophage vaccination was associated with significant tumor-specific immune response in all 12 treated patients from baseline.
March	Antigenics appoints Brian Corvese to the company’s board of directors.
	2006
December	Antigenics appoints Peter Thornton and Timothy R. Wright to its board of directors.
November	Preliminary data from a Phase 1/2 investigator-sponsored trial of Oncophage as a treatment for recurrent glioma are presented at the Immunotherapy Task Force Meeting, held at the Society of Neuro-Oncology’s 11th Annual Scientific Meeting. Preliminary results from the first cohort of six patients in the study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco, showed that vaccination was associated with tumor-specific immune response in all six treated patients.
October	Antigenics announces the sale of $25 million of convertible senior notes to a group of accredited investors.
September	Antigenics appoints Hyam I. Levitsky, MD, to its board of directors.
	Shalini Sharp succeeds Peter Thornton as Antigenics’ chief financial officer.
July	Antigenics announces an expanded license and supply agreements for the use of QS-21 Stimulon^® adjuvant with GlaxoSmithKline Biologicals, a vaccine division of GlaxoSmithKline (GSK). QS-21 is a key component included in several of GSK’s proprietary adjuvant systems. A number of GSK’s vaccine candidates currently under development are formulated with GSK’s proprietary adjuvant systems containing QS-21.
June	Antigenics announces findings from an in-depth analysis of its Phase 3 study of Oncophage vaccine in kidney cancer. Review of the data at an international expert panel meeting on June 2, 2006, found that in the full analysis set, there was a clinically significant, 43-percent improvement in recurrence-free survival associated with Oncophage in a well defined subgroup of better-prognosis patients.
	Antigenics announces in an oral presentation at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) updated findings from a Phase 3 clinical trial of Oncophage in metastatic melanoma. In the study, patients who received at least 10 doses of vaccine experienced an extension in median survival of 29 percent compared with those who received physician’s choice. In a subset analysis, Oncophage was associated with a potentially clinically relevant benefit compared with physician’s choice for patients with stages IV M1a and M1b melanoma, if at least 10 doses of vaccine were administered.
March	Antigenics announces top-line results from its Phase 3 study of Oncophage in kidney cancer patients who are at high risk of recurrence after surgery. The analysis was triggered based on the number of events (defined as recurrence of disease or death of a patient prior to recurrence) reported by study investigators. However, an independent review by the trial’s Clinical Events Committee revealed that a substantially smaller number of events had actually occurred. The preliminary analysis showed a trend in favor of Oncophage for recurrence-free survival (the study’s primary endpoint), and a trend against Oncophage for overall survival (secondary endpoint); both findings were not statistically significant.
	2005
November	Bruce A. Leicher joins Antigenics as Vice President and General Counsel. The Brain Tumor Research Center at the University of California, San Francisco, initiates a Phase 1/2, investigator-sponsored clinical trial of Oncophage as a treatment for patients with recurrent glioma.
October	Antigenics begins a Phase 1 trial of Aroplatin in solid tumors and B-cell lymphoma. Aroplatin, an investigational platinum agent, has been reformulated by Antigenics to enhance the drug’s activation and stability. Antigenics initiates a Phase 1 trial of AG-707, an investigational vaccine designed to treat genital herpes. Jill M. Forrest joins Antigenics as Vice President of Marketing and Sales. Antigenics announces survival data from a preliminary analysis of the Phase 3 trial of Oncophage in metastatic melanoma. The study showed that in all randomized stage IV M1a patients median survival improved by more than 50 percent in the Oncophage-treated arm compared with those in the physician’s choice treatment arm. A final data analysis is expected during the first quarter of 2006.
June	Antigenics announces that Oncophage^® (vitespen; formerly HSPPC-96) has been granted orphan drug status for the treatment of renal cell carcinoma by the European Medicines Agency (EMEA).
May	A publication in Nature Immunology provides support for the immunological mechanism of action of the company’s heat shock protein (HSP)-based vaccines. The paper demonstrates that complexes of HSPs and peptides are the necessary and sufficient form of antigen to activate a killer T-cell immune response in vivo.
January	Antigenics completed a private placement of convertible senior notes due 2025 to third-party investors, raising net proceeds of approximately $48 million.
	2004
September	Antigenics appoints Alastair J. J. Wood to the company’s board of directors.
July	Roman M. Chicz, PhD, is appointed senior vice president of research and preclinical development, a newly created position at Antigenics.
June	Demographic data from the company’s Phase 3 trial of Oncophage in renal cell carcinoma, being conducted by The Antigenics Renal Cell Carcinoma Study Group, were published at the 40th annual meeting of the American Society of Clinical Oncology (ASCO). Also presented were immunological findings from a Phase 2 trial of combination treatment with Oncophage and cytokines in metastatic melanoma.
May	Antigenics announces that Peter Thornton will join the company as chief financial officer and senior vice president. Jeff Clark, who has been CFO since March 2003, has resigned, with plans to return to his home state of Texas.
March	Antigenics announces the sale of its manufacturing rights for feline leukemia virus vaccine to French veterinary pharmaceutical manufacturer Virbac S.A. for $14.25 million in cash.
February	Underwriters of Antigenics’ public offering in January 2004 purchase 400,000 shares of common stock pursuant to a partial exercise of their over-allotment option. Net proceeds to Antigenics from the sale of the additional shares are approximately $4 million.
January	Antigenics completes $52.5 million public offering of common stock.
	2003
December	An independent Data Monitoring Committee convenes as scheduled for the interim analysis of the Phase 3 trial of Oncophage in renal cell carcinoma, and recommends that the trial proceed as planned. The DMC states that there is no need to change the patient accrual goals and declares the design and conduct of the trial sound.
	Data on heat shock protein-based vaccines were presented in a separate poster sessions at the 45th annual meeting of the American Society of Hematology. Preliminary findings from a Phase 1 study of HSPPC-70, an HSP70-based cancer vaccine, in chronic myelogenous leukemia and from a Phase 2 trial of Oncophage in non-Hodgkin’s lymphoma indicate that treatment with the HSP-based vaccines is well tolerated and feasible, and may be associated with clinical response.
November	The US Food and Drug Administration lifts the partial clinical hold on Phase 3 clinical trials of Oncophage, and Antigenics resumes patient enrollment for the studies. The agency’s decision to lift the hold came 13 weeks after its request for product characterization information in September 2003.
	Renu Gupta, MD, joins the company as senior vice president of development. Elma S. Hawkins, PhD, is appointed to senior advisor, and Jonathan J. Lewis, MD, PhD, leaves the company.
October	Antigenics publishes immunological results from Phase 2 trials evaluating Oncophage in the treatment of both advanced melanoma and colorectal cancer in the Journal of Immunology. Significant cancer-specific immune response among patients receiving Oncophage was observed, and the immunological mechanism of action was determined to be the same for both melanoma and colorectal cancer.
September	The US Food and Drug Administration declares a partial clinical hold on Phase 3 clinical trials of Oncophage, stating product characterization issues needed to be more fully documented.
	Antigenics presented results from a Phase 1 trial of Oncophage in patients with nonmetastatic pancreatic cancer in an oral presentation at the annual European Cancer Conference (ECCO 12). Patients in the pilot study, which included 10 evaluable patients, experienced a median overall survival of 2.5 years, with one patient still alive and disease-free after five years, and two other patients alive and disease-free 2.1 years after treatment.
August	Clinical Cancer Research published results from a Phase 2 trial of Oncophage for treatment of colorectal cancer as a featured article in the August 15 issue. In the study, more than half of the 29 patients who received Oncophage demonstrated significant immunological response - which not only appeared to be correlated with clinical response but also found to be an independent factor for prognosis.
June	In an oral presentation at the 39th annual meeting of the American Society of Clinical Oncology (ASCO), Antigenics presented updated results from a pilot study of HSPPC-70, an HSP70-based cancer vaccine, in combination treatment of chronic myelogenous leukemia. Responses were observed in seven of the eight patients evaluated.
	Antigenics also presented at ASCO findings from two Phase 2 studies, which demonstrated that treatment with Oncophage was associated with clinical and immunological response in both kidney cancer and non-Hodgkin’s lymphoma.
April	Antigenics initiates a large, multicenter Phase 2 trial of AG-858 in combination treatment for chronic myelogenous leukemia.
March	Antigenics appoints three new members, Margaret Eisen, Wadih Jordan and Mark Kessel, to its board of directors. Jeff D. Clark promoted to chief financial officer.
January	Antigenics completes $62 million public offering of common stock.
	2002
December	Nine new heat shock protein (HSP)-related patents are issued, expanding Antigenics’ HSP intellectual property portfolio to 45 US-issued patents.
	Antigenics reports significant results from a pilot study of HSPPC-70, an HSP70-based cancer vaccine, in combination treatment with Gleevec™ in chronic myelogenous leukemia patients.
October	Antigenics files an opposition to a European patent licensed to Stressgen Biotechnologies on grounds that its claimed invention is obvious, lacks novelty, is insufficiently described, and encompasses non-patentable subject matter.
	The peer-reviewed Journal of Clinical Oncology publishes results from a Phase 2 trial of Oncophage in metastatic melanoma. In the study, Oncophage treatment was associated with both immunological and clinical response, and no treatment-related toxicity was observed.
July	Antigenics expands its HSP technology platform with 15 patents, allowing Antigenics’ core technology to be applied in novel applications in a broader range of disease areas.
	Deanna Petersen joins Antigenics as vice president of business development.
	The US Food and Drug Administration (FDA) grants Oncophage orphan drug status in metastatic melanoma. The designation provides Antigenics with potential market exclusivity in metastatic melanoma for seven years from FDA marketing approval.
	Antigenics begins trial of Aroplatin monotherapy in metastatic colorectal cancer.
	Frank V. AtLee III, chairman of Monsanto Company, appointed to Antigenics’ board of directors.
	Antigenics CEO Garo Armen named chairman of Elan Corporation.
June	CEO Garo Armen wins NYC Biotechnology Entrepreneur of the Year award from Ernst & Young.
	A study published in Urologic Oncology demonstrates improved quality of life in kidney cancer patients receiving Oncophage treatment.
May	Antigenics receives orphan drug status from the FDA for Oncophage in renal cell carcinoma, providing the company with potential market exclusivity for seven years from FDA marketing approval.
	Antigenics presents promising interim results from trials of Oncophage in metastatic melanoma, colorectal and gastric cancers at the annual ASCO scientific sessions.
	First patient is enrolled into Antigenics’ pivotal Phase 3 trial of Oncophage as a treatment for metastatic melanoma.
April	Antigenics presents positive clinical and immunological data of Oncophage in melanoma and colorectal cancer at the annual meeting of the American Association for Cancer Research (AACR).
February	Oncophage receives fast track designation from the FDA for treatment of metastatic melanoma. This is the second fast track designation for Oncophage, which previously received the designation as a treatment of renal cell carcinoma.
January	Russell Herndon named president and chief operating officer.
	Antigenics completes $60 million public offering of common stock.

	2001
October	Oncophage becomes the first patient-specific cancer product to receive FDA fast track designation.
September	Antigenics elects Samuel D. Waksal, CEO of ImClone Systems, to the board of directors (resigned June 2002).
July	Antigenics and Bruce Walker of Massachusetts General Hospital test HSP-based approach to HIV.
	Acquisition of Aronex Pharmaceuticals is completed.
	QS-21 adjuvant demonstrates a clinical response in Alzheimer’s disease, according to a study conducted by Elan Pharmaceuticals and American Home Products.
May	Antigenics presents Oncophage data from melanoma and colorectal cancer clinical trials at ASCO.
April	Acquisition of Aronex Pharmaceuticals is announced.
April	Antigenics receives National Institutes of Health grant for malaria study using QS-21 technology.
February	Antigenics launches Phase 1 study of AG-702 for genital herpes.
January	Six patents are issued that expand Antigenics’ ability to treat cancers and infectious diseases.
January	Hiring of Russell Herndon as chief operating officer is announced.

	2000
November	Oncophage pancreatic cancer trial is expanded at Memorial Sloan-Kettering Cancer Center.
	Acquisition of Aquila Biopharmaceuticals is completed.
	Antigenics wins European patent dispute with Stressgen relating to the use of HSPs for treatment of cancer and infectious diseases.
October	Antigenics launches Phase 2 clinical trial of Oncophage for treatment of sarcoma at Memorial Sloan-Kettering Cancer Center.
July	CD91 heat shock protein receptor is discovered.
June	Antigenics launches first Phase 3 trial, a study of Oncophage in renal cell carcinoma.
May	Antigenics presents results of clinical trials in renal cell carcinoma and gastric cancer at ASCO scientific sessions.
April	Patent is issued for the use of HSPs in infectious diseases.
April	Antigenics presents clinical data from Oncophage melanoma trial at the annual meeting of the American Association for Cancer Research.
March	Antigenics launches Phase 2 clinical trial of Oncophage for the treatment of non-Hodgkin’s lymphoma.
March	Patents are issued to Antigenics in the field of functional genomics.
February	Antigenics raises $72.5 million in initial public offering of common stock.
January	Patent is issued covering the treatment of autoimmune diseases with HSPs.

	1999
November	Antigenics raises $39.2 million in a round of private financing.
October	Patent is issued for HSP-based vaccine delivery technology.
May	Antigenics opens state-of-the-art research and development/manufacturing facility in Woburn, Massachusetts.
May	Antigenics presents Oncophage data in renal cell carcinoma at ASCO annual meeting.
January	Antigenics raises $27.6 million in round of private financing.

	1998
4Q	Antigenics launches Phase 2 trial of Oncophage in melanoma and colorectal cancer in Milan.
November	Patent is issued for use of HSPs in combination with adoptive immunotherapy.
October	Antigenics establishes autologous cancer vaccine with Sigma Tau, Italy’s second largest pharmaceutical company.
May	Patent is issued for the use of HSPs in the treatment of cancer.

	1997
November	Phase 1 trial of Oncophage for treatment of pancreatic cancer commences at Memorial Sloan-Kettering Cancer Center.

	1996
December	Antigenics raises $10.6 million in round of private financing.
November	Investigational new drug application is filed with the FDA for Oncophage in cancer.

	1995
December	Antigenics raises $1.5 million in round of private financing.

	1994
March	Founding of Antigenics